Niraula Saroj
Medical Oncology and Hematology, University of Manitoba and CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba, Canada, R3E 0V9.
Cancer Med. 2016 Oct;5(10):3018-3020. doi: 10.1002/cam4.859. Epub 2016 Sep 28.
Differing interpretations about evidence on benefits and harms of screening mammography has led to conflicting recommendations among different jurisdictions that range from intensive screening starting at age 40 to no screening at all. Despite broad attention of scientific and nonscientific media, evidence suggests substantial discrepancy between real and perceived benefits of screening mammography among women. In this commentary, underlying concept of mammographic screening, limitations in primary evidence, results from secondary evidence, and existing misunderstandings are underscored with a critical gaze at available information.
对于乳腺钼靶筛查利弊证据的不同解读,导致不同司法管辖区之间出现了相互矛盾的建议,范围从40岁开始进行密集筛查到完全不筛查。尽管科学和非科学媒体都广泛关注,但有证据表明,女性对乳腺钼靶筛查实际益处和感知益处之间存在重大差异。在这篇评论中,我们以批判性的眼光审视现有信息,强调了乳腺钼靶筛查的基本概念、主要证据的局限性、次要证据的结果以及现有的误解。